<DOC>
	<DOCNO>NCT00325858</DOCNO>
	<brief_summary>The purpose study compare effectiveness multiple dos daily tramadol HCl ER ( 100 , 200 , 300 400 mg ) placebo patient moderate severe pain due OA . The study hypothesis tramadol HCl ER safe effective treatment patient moderate severe pain due OA .</brief_summary>
	<brief_title>A Study Comparing Effectiveness Safety Varying Dose Strengths ( 100 , 200 , 300 400 mg ) Extended-release Tramadol HCl With Placebo Treatment Osteoarthritis ( OA ) Knee and/or Hip</brief_title>
	<detailed_description>Immediate release ( IR ) tramadol demonstrate efficacy several pain condition include : obstetrical , gynecological , orthopedic , abdominal , oral surgery . The short elimination half-life tramadol IR necessitate every 4-6 hour dose maintain optimal level analgesia chronic pain . The study medication study once-daily , extended-release tramadol formulation . This 12-week multi-center , double-blind , randomize , dose-ranging , parallel-group , fixed-dose , placebo-controlled study . Patients OA Functional Class I-III knee hip ( index joint ) eligible participation , appropriate criterion meet . During 2-7 day washout period , use analgesic medication discontinue . Eligible patient experience moderate severe pain ( &lt; =40 mm 100 mm visual analog scale ) index joint evaluate meet study criterion enter 2-week , double-blind titration period . During period , patient randomly assign receive treatment tramadol HCl ER 100 mg , 200 mg , 300 mg , 400 mg placebo , day . Patients titrate assign dose study day 1 - 15 continue dose remainder study ( Week 12 ) . Efficacy safety evaluation collect study visit occur Weeks 1 , 2 , 3 , 6 , 9 12 early termination . Study medication discontinue Week 12 patient return 1 week post-treatment visit ( Week 13 ) . Patients unmanageable pain unacceptable side effect discontinue study alternate analgesic therapy initiate , appropriate .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Patients American College Rheumatology ( ACR ) Functional Class IIII OA knee hip Patients involvement least one knee hip joint warrant treatment COX2 inhibitor , NSAIDS , acetaminophen , opioid analgesic least 75 90 day precede screen visit Patients pain intensity score index joint &gt; =40 mm visual analog scale ( VAS ) baseline visit Patients able discontinue acetaminophen , NSAIDS , COX2 selective inhibitor , analgesic washout period throughout study Patients able understand study procedure complete pain scale Patients medical condition , OA , uncontrolled treatment clinically significant condition , investigator 's opinion , precludes study participation interferes assessment chronic pain OA symptoms Patients diagnosis inflammatory arthritis , gout , pseudogout Paget 's disease , , investigator 's opinion , interfere assessment pain symptom OA Patients diagnosis chronic pain syndrome Patients ACR clinical diagnosis fibromyalgia Patients clinically significant form joint disease prior joint replacement surgery index joint Patients anticipate need surgery invasive procedure index joint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>osteoarthritis pain</keyword>
	<keyword>knee</keyword>
	<keyword>hip</keyword>
	<keyword>extended-release analgesia</keyword>
	<keyword>opioid</keyword>
</DOC>